JP2022537142A5 - - Google Patents

Info

Publication number
JP2022537142A5
JP2022537142A5 JP2021573449A JP2021573449A JP2022537142A5 JP 2022537142 A5 JP2022537142 A5 JP 2022537142A5 JP 2021573449 A JP2021573449 A JP 2021573449A JP 2021573449 A JP2021573449 A JP 2021573449A JP 2022537142 A5 JP2022537142 A5 JP 2022537142A5
Authority
JP
Japan
Application number
JP2021573449A
Other languages
Japanese (ja)
Other versions
JPWO2020251924A5 (https=
JP7807238B2 (ja
JP2022537142A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/036771 external-priority patent/WO2020251924A1/en
Publication of JP2022537142A publication Critical patent/JP2022537142A/ja
Publication of JP2022537142A5 publication Critical patent/JP2022537142A5/ja
Publication of JPWO2020251924A5 publication Critical patent/JPWO2020251924A5/ja
Priority to JP2025112473A priority Critical patent/JP2025138816A/ja
Application granted granted Critical
Publication of JP7807238B2 publication Critical patent/JP7807238B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573449A 2019-06-12 2020-06-09 骨形成タンパク質6に対するヒト抗体 Active JP7807238B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025112473A JP2025138816A (ja) 2019-06-12 2025-07-02 骨形成タンパク質6に対するヒト抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962860597P 2019-06-12 2019-06-12
US62/860,597 2019-06-12
PCT/US2020/036771 WO2020251924A1 (en) 2019-06-12 2020-06-09 Human antibodies to bone morphogenetic protein 6

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025112473A Division JP2025138816A (ja) 2019-06-12 2025-07-02 骨形成タンパク質6に対するヒト抗体

Publications (4)

Publication Number Publication Date
JP2022537142A JP2022537142A (ja) 2022-08-24
JP2022537142A5 true JP2022537142A5 (https=) 2023-06-15
JPWO2020251924A5 JPWO2020251924A5 (https=) 2023-06-15
JP7807238B2 JP7807238B2 (ja) 2026-01-27

Family

ID=71944214

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021573449A Active JP7807238B2 (ja) 2019-06-12 2020-06-09 骨形成タンパク質6に対するヒト抗体
JP2025112473A Pending JP2025138816A (ja) 2019-06-12 2025-07-02 骨形成タンパク質6に対するヒト抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025112473A Pending JP2025138816A (ja) 2019-06-12 2025-07-02 骨形成タンパク質6に対するヒト抗体

Country Status (6)

Country Link
EP (1) EP3983436A1 (https=)
JP (2) JP7807238B2 (https=)
AU (1) AU2020292246A1 (https=)
CA (1) CA3141266A1 (https=)
MA (1) MA56203A (https=)
WO (1) WO2020251924A1 (https=)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
WO2007081751A2 (en) 2006-01-05 2007-07-19 The Johns Hopkins University Compositions and methods for the treatment of cancer
US7420040B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
EP2136788B1 (en) 2007-03-30 2011-10-26 Bind Biosciences, Inc. Cancer cell targeting using nanoparticles
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US20140086919A1 (en) 2012-09-24 2014-03-27 Herbert Y. Lin Methods and compositons for regulating iron homeostasis by modulation of bmp-6
AU2016211890B2 (en) * 2008-11-13 2018-03-22 The General Hospital Corporation Methods and Compositions for Regulating Iron Homeostasis by Modulation of BMP-6
AR093620A1 (es) 2012-12-17 2015-06-10 Lilly Co Eli Anticuerpos bmp-6
UY36449A (es) * 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
GB2550114A (en) 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021015500A2 (https=)
BR102021007058A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016375A2 (https=)
BR102021016200A2 (https=)
BR102021016176A2 (https=)
BR102021015566A2 (https=)